TKTerufumi Kawamoto

Terufumi Kawamoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Terufumi Kawamoto has a total of 147 co-authors. Here are the top co-authors by number of shared publications:

  • Naoto Shikama

    21 shared publications
  • Keisuke Sasai

    Department of Radiation Oncology, Graduate School of Medicine, Juntendo University, Tokyo, Japan

    13 shared publications
  • Masaki Oshima

    Department of Radiation Oncology, Juntendo University Graduate School of Medicine , Tokyo, 113-8421

    9 shared publications
  • Katsuyuki Karasawa

    Division of Radiation Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan

    6 shared publications
  • Keiji Nihei

    Division of Radiation Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo 113‑8677, Japan

    6 shared publications
  • Naoki Nakamura

    Department of Radiation Oncology, St. Marianna University School of Medicine , Kanagawa, 216-8511

    6 shared publications

Latest Publications

  • Comparison of response criteria in palliative radiotherapy for bleeding gastric cancer: a secondary analysis of the JROSG 17-3 multicenter prospective observational study

    by Yutaro Koide, Tetsuo Saito, Takashi Kosugi, Naoki Nakamura, Takeo Takahashi, Terufumi Kawamoto, Nobuko Utsumi, Shuhei Sekii, Hitoshi Wada, Ayako Tonari, et al.

    Objectives: In radiotherapy for bleeding gastric cancer, no standard definition of response exists; studies have used transfusion-only or transfusion-plus-hemoglobin criteria. After inter-facility transfer or during home care—sometimes following palliative radiotherapy—laboratory results from other facilities are often unavailable, leaving patients inevaluable. We therefore tested whether omitting hemoglobin compromises the precision of response assessment. Methods: In criteria A, referring to our original study, patients were diagnosed as responders when all the following 3 conditions were met: (1) hemoglobin levels ≥ 8.0 g/dL; (2) 14 consecutive days without blood transfusion before blood sampling; and (3) no salvage treatment. In criteria B, patients were diagnosed as responders when only (2) and (3) of the above conditions were met. The strength of agreement between criteria A and B was estimated by calculating Gwet’s first-order agreement coefficient (AC1) at 4- and 8-week follow-up for patients completing planned radiotherapy with assessable response. Results: In 36 evaluable patients at 4-week follow-up, response rates were 69% (25/36) by criteria A vs. 78% (28/36) by criteria B (AC1, 0.86; almost perfect agreement). In 30 evaluable patients at 8-week follow-up, response rates were 83% (25/30) by criteria A vs. 90% (27/30) by criteria B (AC1, 0.91; almost perfect agreement). Conclusions: Criteria A and B showed almost perfect agreement at 4- and 8-week assessments among evaluable patients with available hemoglobin data. Advances in knowledge: Among patients with available hemoglobin data, criteria A and B showed almost perfect agreement. The observed agreement may not be fully generalizable to patients without hemoglobin assessment.

  • Open Access

    A Multicenter Phase II Study Evaluating the Efficacy of Single-Fraction 8 Gy Radiotherapy for Bleeding Gastrointestinal Malignancies: STABLE Study Protocol (Preprint)

    by Shota Miyoshi, Nobuki Imano, Tetsuo Saito, Hiroki Ochi, Terufumi Kawamoto, Yuki Wada, Ippei Takahashi, Takashi Kosugi, Kenta Konishi, Tsuyoshi Katsuta, et al.

    BACKGROUND Bleeding is a common complication of advanced gastrointestinal malignancies. Although radiotherapy is an effective hemostatic treatment, dose-fractionation remains unclear. Single-fraction 8 Gy radiotherapy has been demonstrated in palliative irradiation for conditions such as bone and liver metastases; however, its effectiveness in hemostatic radiotherapy remains uncertain. OBJECTIVE This study aims to prospectively evaluate the efficacy and safety of single-fraction 8 Gy radiotherapy for bleeding gastrointestinal malignancies. METHODS This is a prospective, multicenter, single-arm, open-label phase II trial evaluating single-fraction 8 Gy radiotherapy for bleeding gastrointestinal malignancies. A total of 47 patients will be enrolled from 12 institutions in Japan. The primary endpoint is the hemostasis rate at 4 weeks after radiotherapy in the intention-to-treat population. Secondary endpoints include hemostasis rates at other time points, changes in hemoglobin levels, transfusion requirements, incidence of rebleeding, rebleeding-free interval, salvage treatment use, overall survival, antiemetic use, patient-reported toxicity, and health-related quality of life. RESULTS The study protocol was approved by the Hiroshima University Hospital Institutional Review Board in October 2025, and patient enrollment began in the same month. Recruitment is ongoing. CONCLUSIONS The STABLE study will provide prospective evidence regarding the efficacy and safety of single-fraction 8 Gy radiotherapy for bleeding gastrointestinal malignancies. The findings may help increase access to a less burdensome hemostatic approach for patients with bleeding gastrointestinal malignancies. CLINICALTRIAL This trial was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR; UMIN000059269).

  • Open Access

    Late-Onset Radiation-Induced Leukoencephalopathy in a Long-Term Survivor with HER2-Positive Breast Cancer and Brain Metastases: A Case Report

    by Miki Shimbara, Ritsuko Sasaki, Terufumi Kawamoto, Naoto Shikama, Misato Okazaki, Kotaro Ijima, Junichiro Watanabe, Goro Kutomi

    Introduction: Recent advances in systemic therapies, particularly antibody-drug conjugates (ADCs), have substantially improved survival in patients with HER2-positive breast cancer and central nervous system (CNS) metastases. With increasing longevity, late adverse effects of cranial radiotherapy have emerged as clinically significant determinants of outcome. Case Presentation: A 43-year-old Japanese premenopausal woman with HER2-positive breast cancer developed multiple brain metastases 2 years after curative surgery and adjuvant chemotherapy and radiotherapy. She underwent hippocampal-avoidance whole-brain radiotherapy (HA-WBRT, 30 Gy in 10 fractions), followed by trastuzumab emtansine. Two years later, stereotactic radiotherapy (SRT, 30 Gy in 3 fractions) was administered for two new adjacent lesions. Six months later, leptomeningeal dissemination was detected, and trastuzumab deruxtecan was initiated, achieving a durable intracranial complete response. However, 4 years after HA-WBRT, she developed progressive cognitive decline and executive dysfunction, with the Mini-Mental State Examination score declining from a baseline of 30 to 18 within 2 months. Brain magnetic resonance imaging revealed diffuse, bilateral, relatively symmetric periventricular and deep white matter changes without evidence of tumor recurrence, consistent with late-onset radiation-induced leukoencephalopathy (RIL). Her neurological condition progressively deteriorated, with loss of social functioning and decision-making capacity, ultimately leading to discontinuation of active treatment and transition to best supportive care within 4 months of the diagnosis of RIL. She died approximately 2 months later, following progression of leukoencephalopathy. Conclusion: This case highlights that severe late-onset RIL can occur following HA-WBRT and salvage SRT in long-term survivors with breast cancer and CNS metastases. Although intracranial disease control was maintained for several years, progressive cognitive dysfunction led to discontinuation of active treatment. As survival improves in patients with breast cancer and CNS metastases, long-term management may need to consider not only intracranial disease control but also the risk of late neurological toxicity.

  • Open Access

    Local control of locally advanced uterine sarcoma achieved by cervical brachytherapy with gel spacer following cyclic hypofractionated radiation therapy (QUAD shot) in a patient who refused surgery

    by Yasuo Kosugi, Naoya Murakami, Tatsuki Karino, Yoichi Muramoto, Terufumi Kawamoto, Masaki Oshima, Noriyuki Okonogi, Anneyuko I Saito, Jun Takatsu, Tatsuya Inoue, et al.

    Radiation therapy is not mentioned in various guidelines for primary treatment of uterine sarcoma. Radiation therapy is considered useful for palliative purposes, but an optimal radiation schedule has not been established. An 85-year-old woman was recommended to undergo surgery for locally advanced uterine sarcoma of unknown histological subtype, but she refused because of her poor physical and social circumstances. She instead received chemotherapy; however, the lesion progressed, and the patient opted for best supportive care. Palliative radiation therapy was indicated for genital bleeding. She thereafter received the QUAD shot regimen, in which 3.7 Gy was administered twice a day for 2 consecutive days and repeated every 4 weeks for a total dose of 44.4 Gy in 3 cycles. The lesion significantly decreased in size, and no new regional or distant metastases were identified. Although only palliative radiation therapy was initially intended, the favourable response with no new lesion development prompted us to offer additional brachytherapy for curative intent, and the patient accepted. She underwent 2 sessions of uterine cervical intracavitary and interstitial brachytherapy using a gel spacer, and local control of the lesion was achieved at 1-year and 3 months follow-up of treatment without major adverse events. In select patients for whom a favourable response is achieved after the QUAD shot, the addition of intracavitary and interstitial brachytherapy with a gel spacer may result in curative treatment. This therapy could be a very promising and attractive option for patients with uterine sarcoma who have complications or special social circumstances.

  • Open Access

    The role of external-beam radiotherapy for differentiated thyroid cancer

    by Terufumi Kawamoto, Naoto Shikama, Naoki Nakamura, Takashi Mizowaki

    The treatment options for differentiated thyroid cancer (DTC) are surgery, thyroid stimulating hormone suppression, radioactive iodine, and multitargeted tyrosine kinase inhibitors. The role of external-beam radiotherapy (EBRT) for DTC is controversial because of the lack of randomized controlled trials, but prospective single-arm studies and propensity score matching analyses have shown its efficacy and safety. This review discusses the role of EBRT after resection of gross disease, when there is a high risk of locoregional failure, as well as its role for locoregionally gross recurrent and unresectable disease. As in other tumor sites, EBRT has an important role in the palliative management and local control of patients with metastatic DTC, especially with bone and brain metastases.


  • Development and promotion of a 3D-printed phantom model for ultrasound-guided caudal block followed by intracavitary/interstitial brachytherapy for gynecological cancer

    by Terufumi Kawamoto, Masaki Oshima, Naoya Murakami, Noriyuki Okonogi, Yoichi Muramoto, Tatsuki Karino, Kotaro Iijima, Jun Takatsu, Tatsuya Inoue, Naoto Shikama


  • Open Access

    Dose Contribution to the Regional Lymph-Node Metastases and Point B from Intracavity and Interstitial Hybrid Brachytherapy in Locally Advanced Cervical Cancer

    by Yoichi Muramoto, Naoya Murakami, Noriyuki Okonogi, Jun Takatsu, Kotaro Iijima, Tatsuya Inoue, Kanade Kato, Tatsuki Karino, Kanako Kojima, Masaki Oshima, et al.

    Purpose: Analyzing dose distributions to regional lymph-node metastases (RLNMs) in locally advanced cervical cancer (LACC) patients undergoing intracavitary and interstitial hybrid brachytherapy (IC/IS). Methods: Dose distributions of eleven LACC patients with 38 RLNMs, and who received 38 IC/IS sessions were analyzed in EQD2, considering RLNM positions and ipsilateral interstitial needles; these RLNMs, excepting the para-aortic region, were classified into four groups. Results: RLNMs had a median of two ipsilateral interstitial needles per session. Significant differences were observed in total RLNM D90, depending on whether the position was cranial or caudal of the uterine base (85.5 vs. 378.9 cGy, p < 0.0001), and whether the RLNM D90 was associated with a number of ipsilateral interstitial needles between 0–1 or 2 or more (68.4 vs. 112.2 cGy, p = 0.006) per session. At each session, Group 1 RLNMs (cranial of the uterine base, 0–1 ipsilateral interstitial needle) had a mean D90 of 21.1 cGy; Group 2 (cranial, 2 or more), 73.8; Group 3 (caudal, 0–1), 94.7; and Group 4 (caudal, 2 or more), 136.1. Conclusion: RLNMs located caudal of the uterine base associated with two or more ipsilateral interstitial needles in IC/IS had a higher dose contribution, which should be considered when calculating the RLNMs’ dose of external beam boost irradiation.


  • In Regard to Zhao et al.

    by Terufumi Kawamoto, Naoya Murakami, Yoichi Muramoto, Tatsuki Karino, Naoto Shikama


  • Open Access

    MucoUp® as a spacer in brachytherapy for uterine cervical cancer: A first-in-human experience

    by Yoichi Muramoto, Naoya Murakami, Tatsuki Karino, Satoru Sugimoto, Jun Takatsu, Masaki Oshima, Yasuo Kosugi, Terufumi Kawamoto, Takashi Hirayama, Kazunari Fujino, et al.